Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

EVITA clinical trial evaluates oral vitamin C for pre-cancerous blood disorders (opens in a new tab)

news-medical.net · 2026-09-21

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Four of six claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 4 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredParticipants who received vitamin C experienced changes in inflammatory signaling that the article says aligns with better outcomes, and certain events such as anemia, pneumonia, acute aseptic arthritis, and internal bleeding were less frequent, while gastrointestinal problems were more frequent.View evidenceHide evidence

Why this verdict

The abstract-level profile supports only the broad points that inflammatory cytokine trajectories differed between arms and that serious adverse events were fewer in the vitamin C arm. It does not identify specific cytokines, direction or magnitude of inflammatory signaling changes, whether they align with better outcomes, or the specific adverse-event categories listed by the story such as anemia, pneumonia, acute aseptic arthritis, internal bleeding, or increased gastrointestinal problems. Those details may come from the full paper, but they are not verifiable from the supplied abstract-depth profile.

1

Study evidence

Fewer serious adverse events (SAEs) occurred in the vitamin C arm than in the placebo arm during the 12-month treatment period.18 of 55 (33%) in VitC vs 30 of 53 (57%) in placebo (as reported in abstract)

“secondary outcomes included ... fewer serious adverse events in the VitC group versus placebo (18 of 55 [33%] vs. 30 of 53 [57%]).”
2

Study evidence

Secondary outcomes reported differences in inflammatory cytokine trajectories between the vitamin C and placebo arms over the trial period.

“secondary outcomes included differences in inflammatory cytokine trajectories”
Claim 2 of 6Not coveredAt a median follow-up of 33.6 months, 35 deaths were recorded, including 24 in the placebo group and 11 in the vitamin C group.View evidenceHide evidence

As stated33.6 months; 35 deaths total; 24 placebo; 11 vitamin C

Why this verdict

The supplied profile reports an exploratory overall-survival advantage but explicitly notes that the abstract does not provide follow-up duration or event counts. Therefore the stated median follow-up of 33.6 months and death counts of 35 total, 24 placebo, and 11 vitamin C are not verifiable at the supplied abstract evidence depth.

1

Study evidence

In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025

“followed by long-term follow-up”
Claim 3 of 6SupportedResearchers tested oral vitamin C supplements in patients at risk of developing blood cancers because vitamin C boosts TET enzyme activity and reduced TET function is a common driver of certain blood cancers.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the rationale: vitamin C is described as a cofactor for TET enzymes involved in DNA demethylation, with preclinical motivation for leukemia progression, and TET2 mutations/reduced TET function are described as relevant drivers in leukemia/myeloid disease context. The story frames this as rationale for testing vitamin C, not as proof of clinical benefit.

1

Study evidence

Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
2

Study evidence

In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025

“followed by long-term follow-up”
Claim 4 of 6SupportedAn exploratory analysis found that participants in the vitamin C group were more likely to survive during follow-up than those in the placebo group, but the article says this finding requires confirmation in a larger phase 3 trial.View evidenceHide evidence

Why this verdict

The profile states that exploratory long-term follow-up found longer overall survival with vitamin C versus placebo, HR 0.35, 95% CI 0.17 to 0.71, p=.0025, and that the authors conclude a phase 3 trial is warranted. The story’s lead-level claim is appropriately hedged as exploratory and requiring confirmation rather than presenting a definitive survival benefit.

1

Study evidence

In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025

“followed by long-term follow-up”
Claim 5 of 6SupportedThe EVITA trial was a randomized, double-blind, placebo-controlled phase 2 clinical trial that enrolled 109 patients in Denmark and the United States, with 55 assigned to oral vitamin C (1,000 mg/day) and 54 to placebo for 12 months.View evidenceHide evidence

As stated109 patients; 55 vitamin C; 54 placebo; 1,000 mg/day; 12 months

Why this verdict

The profile identifies EVITA as a randomized, double-blind, placebo-controlled phase 2 trial in Denmark and the United States, with 109 enrolled participants randomized 1:1 to oral vitamin C 1000 mg/day for 12 months versus placebo, including 55 in the vitamin C arm and 54 in the placebo arm.

1

Study evidence

Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
Claim 6 of 6SupportedThe primary endpoint-growth rate of precancerous or cancerous cells-was similar between groups.View evidenceHide evidence

Why this verdict

The paper profile states that the prespecified primary endpoint was median clonal growth rate from baseline to end of treatment and that it did not differ between groups, with effect estimate -0.016, 95% CI -0.096 to 0.064, p=0.70. The story’s phrasing of similar growth rate of precancerous or cancerous cells is a reasonable lay rendering of clonal growth rate.

1

Study evidence

Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Secondary biomarker analyses reported differences in inflammatory cytokine trajectories between arms, but the abstract does not provide cytokine identities, direction, magnitude, p-values, or modeling details.

    The story reflects that inflammatory signaling changed, but it does not convey the abstract-depth uncertainty and missing detail around which cytokines changed, how they changed, or how robust the trajectory analyses were. It also adds an interpretation about alignment with better outcomes that is not verifiable from the abstract profile.

    From Randomized, double-blind, placebo-controlled phase 2 trial

  • Safety evidence was secondary and limited at abstract depth: no p-value or statistical test for the serious-adverse-event comparison, limited AE definition/adjudication detail, modest phase 2 sample size, and denominator mismatch not explained.

    The story mentions increased gastrointestinal problems but does not report these limitations of the safety comparison, which affect how definitively the adverse-event differences can be interpreted.

    From Double-blind randomized placebo-controlled phase 2 trial

6 things the story did carry across
  • EVITA was a phase 2 randomized, double-blind, placebo-controlled trial of oral vitamin C 1000 mg/day versus placebo for 12 months in adults with CCUS or lower-risk myeloid malignancies.
  • The prespecified primary endpoint was median clonal growth rate from baseline to the end of 12-month treatment, and it did not differ between groups.
  • The biological rationale involved vitamin C as a TET-enzyme cofactor and TET-related dysfunction as relevant to myeloid malignancy biology.
  • Safety outcomes in the abstract showed fewer serious adverse events in the vitamin C arm than placebo, 18/55 (33%) versus 30/53 (57%).
  • Exploratory long-term follow-up reported longer overall survival with vitamin C, HR 0.35, 95% CI 0.17 to 0.71, p=.0025.
  • The survival analysis was exploratory in a phase 2 trial, and the authors stated that a phase 3 trial is warranted to confirm findings.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate whether 12 months of oral vitamin C vs placebo alters clonal dynamics (clonal growth rate) in adults with CCUS or lower-risk myeloid malignancies.Phase 2 randomized double-blind placebo-controlled trialExpand

In plain English

Phase 2 double-blind randomized placebo-controlled trial (EVITA) testing whether 12 months of oral vitamin C (1000 mg/day) versus placebo alters clonal dynamics (median clonal growth rate) in adults with CCUS or lower-risk myeloid malignancies not receiving anticancer therapy. The primary endpoint (median clonal growth rate from baseline to end of 12-month treatment) did not differ between groups.

Key findings

  • Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70
“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
What this piece can’t prove
  • Phase 2 trial; authors state a phase 3 trial is warranted to confirm findings.
2human in vivoAssess safety/tolerability of oral vitamin C vs placebo (including serious adverse events).Double-blind randomized placebo-controlled phase 2 trialExpand

In plain English

EVITA was a double-blind, randomized, placebo-controlled phase 2 trial comparing oral vitamin C (1000 mg/day) versus placebo for 12 months in adults with CCUS or lower-risk myeloid malignancies not receiving anticancer therapy. Safety/tolerability outcomes reported in the abstract indicate fewer serious adverse events (SAEs) in the vitamin C arm than placebo during the treatment period.

Key findings

  • Fewer serious adverse events (SAEs) occurred in the vitamin C arm than in the placebo arm during the 12-month treatment period.18 of 55 (33%) in VitC vs 30 of 53 (57%) in placebo (as reported in abstract)
“secondary outcomes included ... fewer serious adverse events in the VitC group versus placebo (18 of 55 [33%] vs. 30 of 53 [57%]).”
What this piece can’t prove
  • Abstract-only report: limited methodological detail on adverse event collection, definitions, and adjudication.
  • Relatively small sample size for safety endpoints (phase 2), limiting precision of effect estimates for harms.
  • Potential differences in follow-up or censoring between arms not described in abstract.

1 further detail could not be confirmed from the summary.

3human in vivoAssess biological activity signals of vitamin C vs placebo, including inflammatory cytokine trajectories.Randomized, double-blind, placebo-controlled phase 2 trialExpand

In plain English

In the EVITA randomized, double-blind, placebo-controlled phase 2 trial (oral vitamin C 1000 mg/day vs placebo for 12 months, n=109), the abstract reports secondary outcome differences in inflammatory cytokine trajectories between the vitamin C and placebo arms, interpreted as a biological activity signal. The abstract does not report which cytokines, the direction or magnitude of changes, or statistical estimates for these biomarker trajectories.

Key findings

  • Secondary outcomes reported differences in inflammatory cytokine trajectories between the vitamin C and placebo arms over the trial period.
“secondary outcomes included differences in inflammatory cytokine trajectories”
What this piece can’t prove
  • As a secondary outcome, the cytokine results may be exploratory; the abstract does not state whether these analyses were pre-specified or adjusted for multiple comparisons.

2 further details could not be confirmed from the summary.

4human in vivoExplore longer-term clinical outcomes after treatment, including overall survival, during follow-up.Double-blind, randomized, placebo-controlled phase 2 trial with long-term follow-up and exploratory time-to-event (overall survival) analysisExpand

In plain English

Exploratory long-term follow-up of the randomized, double-blind, placebo-controlled EVITA phase 2 trial (n=109) reports a longer overall survival with oral vitamin C (1000 mg/day for 12 months) versus placebo (exploratory HR 0.35; 95% CI 0.17–0.71; p = .0025). The analysis is labeled exploratory in the abstract; details on follow-up duration, censoring, and modeling are not provided there.

Key findings

  • In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025
  • The primary trial endpoint, median clonal growth rate from baseline to end of treatment, showed no difference between vitamin C and placebo.-0.016 (95% CI -0.096 to 0.064); p = .70
“followed by long-term follow-up”
What this piece can’t prove
  • Abstract does not report follow-up duration, number of events, censoring patterns, or details of the survival model.
  • Phase 2 trial with relatively small randomized sample (n=109); event counts and power for survival differences not provided in abstract.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Selected

Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.

Cancer · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Clonal Hematopoiesis of Indeterminate Potential, Clonal Cytopenia of Undetermined Significance, and Precursor States of Myeloid Neoplasms

Handbook of Hematologic Malignancies · 2025 · Crossref

Source (opens in a new tab)
Candidate

A Case Report of Hereditary Spherocytosis Complicated with Clonal Cytopenia of Undetermined Significance

2026 · Crossref

Source (opens in a new tab)
Candidate

Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets

Frontiers in Hematology · 2024 · Crossref

Source (opens in a new tab)
Candidate

Diagnostic Approach, Clinical Implications and Management of Clonal Cytopenia of Undetermined Significance

Healthbook TIMES Oncology Hematology · 2022 · Crossref

Source (opens in a new tab)
Candidate

Cancer Labeling, Risk Perception, and Treatment Choices in Clonal Cytopenia of Undetermined Significance

JAMA Network Open · 2025 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.